GoodRx Holdings, Inc. (GDRX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate strong growth prospects, particularly in manufacturer solutions and strategic initiatives, despite some headwinds like Rite Aid bankruptcy. The positive sentiment is reinforced by management's optimistic guidance and strategic focus on market expansion and partnerships. The market cap suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
Key Financial Performance
Total Revenue $196 million, up approximately $1 million versus the prior year. The increase was driven by disciplined execution despite headwinds like Rite Aid store closures and lower transaction volume in the integrated savings program with a PBM partner.
Prescription Transaction Revenue Down 9% year-over-year. The decline was primarily driven by the impact of Rite Aid store closures and lower transaction volume in the integrated savings program with one of the PBM partners.
Manufacturer Solutions Revenue $43.4 million, representing growth of 54% compared to the prior year. This growth was due to strong execution and expansion across both new and existing brand partnerships. Several deals closed earlier than expected, contributing to the strong performance.
Adjusted EBITDA $66.3 million, an increase of 2% versus the prior year, with an adjusted EBITDA margin of 33.8%. This improvement reflects strong cost discipline and operational efficiency.
Cash on Hand $273.5 million at the end of the third quarter, with about $80 million of unused capacity available under the revolving credit facility.
Share Repurchase Approximately 13.4 million shares repurchased at an average price of $4.61 per share, totaling $61.6 million. Approximately $81.4 million of capacity remained under the $450 million share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
RxSmartSaver counter solution: Launched at Kroger pharmacies nationwide, providing instant access to GoodRx savings at the pharmacy counter.
GoodRx for hair loss: A new subscription offering providing clinically proven treatments for hair loss through an integrated digital platform.
Weight loss subscription offering: Combines GLP-1 savings programs with the GoodRx brand to deliver a low-cost solution for weight loss.
Partnership with Novo Nordisk: Offers Ozempic and Wegovy at $499 per month, addressing the lack of insurance coverage for these drugs for weight loss.
Partnership with Amgen: Provides Repatha at nearly 60% off the retail pharmacy list price, overcoming insurance hurdles.
CommunityLink for independent pharmacies: Introduced a cost-plus pricing model to improve pricing predictability and economics for independent pharmacies.
Manufacturer Solutions revenue growth: Achieved 54% year-over-year growth in Q3, driven by new and expanded brand partnerships.
E-commerce experience for retail pharmacies: Allows consumers to check inventory, validate prescriptions, and pay online, improving convenience and reducing pharmacy costs.
Rx Smart Saver program: Improves patient experience and retail partner economics by offering instant access to savings at the pharmacy counter.
Engagement with U.S. healthcare policy: Actively involved in shaping policy efforts to expand access and affordability, aligning with initiatives like TrumpRx and MFN pricing.
Focus on direct-to-consumer models: Positioned to lead in price transparency and consumer-direct healthcare, leveraging GoodRx's platform and partnerships.
Brand campaign - Savings Wrangler: Launched to enhance consumer connection and reinforce GoodRx as a trusted name in prescription savings.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Rite Aid store closures: The ongoing and now complete Rite Aid store closures have reduced prescription volume across certain geographies, impacting the company's ability to maintain user engagement and prescription transactions.
Changes to health insurance coverage: Uncertainty around the future of health insurance coverage in the U.S., including potential changes to the Affordable Care Act marketplace subsidies and Medicaid support, could lead to more Americans being uninsured or facing higher out-of-pocket costs, increasing affordability challenges.
Integrated savings program challenges: Lower transaction volume in the integrated savings program with one of the PBM partners has negatively impacted prescription transaction revenue.
Regulatory and policy changes: The introduction of TrumpRx and most favored nation pricing mandates could create challenges in adapting to new regulatory requirements, despite potential long-term benefits.
Competitive pressures in GLP-1 drug class: The GLP-1 drug class, including drugs like Ozempic and Wegovy, is divisive with insurers in terms of coverage, creating challenges in meeting growing demand and ensuring affordability for patients.
Quarterly variability in Manufacturer Solutions revenue: Manufacturer Solutions revenue is subject to quarterly variability due to deal timing, which can create unpredictability in financial performance.
Shrinking insurance benefits and cash pay dynamics: Consumers facing higher out-of-pocket costs and shrinking insurance benefits may shift toward cash pay prescriptions, which could impact the company's revenue model and require strategic adjustments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company expects full-year revenue to be at least $792 million, with fourth-quarter revenue expected to decline sequentially from the third quarter due to the acceleration of manufacturer solutions deals that closed earlier than anticipated.
Adjusted EBITDA Projections: Full-year adjusted EBITDA is projected to grow by approximately 2% to 6% compared to 2024, with an adjusted EBITDA margin roughly in line with the year-to-date trend.
Manufacturer Solutions Revenue Growth: Manufacturer Solutions revenue is projected to grow approximately 35% year-over-year in 2025, reflecting strong execution and expansion across new and existing brand partnerships.
Market Trends and Policy Environment: The company anticipates long-term tailwinds from policy developments such as TrumpRx and most favored nation mandates, which are expected to drive greater price transparency and direct-to-consumer affordability programs. These trends are seen as supportive of GoodRx's long-term growth opportunities.
Strategic Investments: GoodRx plans to invest further in manufacturer solutions capabilities, expanding its end-to-end e-commerce model to connect manufacturers with patients and healthcare professionals. These investments are expected to fuel growth into 2026 and beyond.
Subscription Offerings: The company plans to launch a third subscription offering for weight loss in the coming weeks, combining GLP-1 savings programs with the GoodRx brand to deliver a convenient, low-cost solution.
Retail Pharmacy Partnerships: GoodRx aims to roll out counter savings programs with additional retailers in the fourth quarter, building on the Rx Smart Saver program launched with Kroger.
Consumer Trends: The company expects a renewed shift toward cash-pay prescriptions due to higher out-of-pocket costs and shrinking insurance benefits, which is anticipated to support long-term growth.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: During the quarter, we repurchased approximately 13.4 million shares of our stock at an average price of $4.61 per share, totaling $61.6 million. At the end of the third quarter, approximately $81.4 million of capacity remained under our $450 million share repurchase program.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the dynamics of the PTR environment and how does it translate into GoodRx's ability to win?
A:The CFO and CEO discussed that 2025 has been challenging due to changes in reimbursement models, increased consumer prices, and high utilization by payers. They anticipate a shift in 2026 with more uninsured individuals and higher out-of-pocket costs, which could expand the cash market. GoodRx aims to capture more market share by focusing on strategic priorities like owning the pharmacy counter and increasing manufacturer solutions revenue.
Q:Where does GoodRx see its competitive advantage in manufacturer solutions?
A:GoodRx's competitive advantage lies in being the #1 digital prescription marketplace for pricing, delivering high ROI to manufacturers, and being the most utilized drug marketplace by prescribers. These factors position GoodRx favorably against competitors.
Q:What are the thoughts on PBMs moving from rebate models to point-of-sale discounts?
A:The CEO and CFO support the shift, seeing it as a move towards more affordability and transparency. GoodRx is well-positioned to benefit from this change due to its existing partnerships with top PBMs and its role as a complement to insurance.
Q:How does GoodRx plan to work with TrumpRx?
A:GoodRx is actively engaging with HHS to integrate with TrumpRx via APIs. TrumpRx will act as a repository of pricing, linking to third parties like GoodRx for cash transactions. GoodRx believes it is well-positioned to benefit from this initiative.
Q:What is the outlook for the ISP market and potential new products?
A:The ISP market's original thesis remains valid, but PBMs are rethinking its ubiquity. GoodRx sees opportunities to expand ISP to include more brands and is considering direct partnerships with employers for cash lists. Details will be outlined in the 2026 plan.
Q:What are the headwinds and tailwinds for 2026 modeling?
A:Headwinds include lapsing revenue from ISP and Rite Aid in 2025. Tailwinds include strategic initiatives and opportunities in ACA, Medicaid, and uninsured markets. GoodRx aims to overcome these headwinds with meaningful strategic initiatives.
Q:What progress has GoodRx made in serving HCPs within its PMS business?
A:GoodRx has invested in technological capabilities to better serve HCPs, setting up for a strong 2026 selling season. Early results are promising, and the company is well-positioned for the upcoming RFP season.
Q:What is the impact of timing shifts in manufacturer deals on Q3 vs. Q4?
A:Some manufacturer deals closed earlier than expected, pulling revenue into Q3. These are not one-time revenues but part of ongoing relationships. Manufacturer solutions revenue is expected to grow above the 35% forecast for the year.
Q:What is the status of the ISP partner relationship?
A:The ISP partner has taken a multi-network approach, but the relationship with GoodRx remains fine. The company assumes the current status quo and sees potential upside if the relationship narrows again.
Q:How does GoodRx approach marketing spend and customer acquisition costs?
A:GoodRx focuses on brand investment and effective spending. Despite a 9% decline in PTR, the company has increased market share in a contracting market, positioning itself for growth in 2026.
Q:What is the expected growth pattern for manufacturer solutions in 2026?
A:Manufacturer solutions are expected to grow throughout 2026, although the timing of deal closures may cause some lumpiness. The segment is a key growth engine for GoodRx.
Q:What is the contribution of point-of-sale discount programs to manufacturer solutions growth?
A:Point-of-sale discount programs, such as partnerships with Novo and Amgen, are significant contributors to growth. These programs improve access and affordability, driving momentum in manufacturer solutions.
Q:What are the trends in GoodRx search volumes and their impact?
A:Search volumes have increased due to a new brand campaign, leading to higher unaided awareness and access. This supports GoodRx's position as a platform for manufacturers to showcase their drug portfolios.
Q:How does GoodRx balance reinvestment in manufacturing solutions with overall financial stewardship?
A:GoodRx invests in capabilities like directed media and HCP engagement while balancing SG&A with bottom-line outcomes. The company ensures that added costs drive favorable returns.
Q:What initiatives are in place to address Rite Aid headwinds?
A:GoodRx targets recapturing volume through outreach and increasing brand awareness. Counter initiatives and direct retailer contracts are key strategies to offset the impact of Rite Aid closures.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the financial impact of timing shifts in manufacturer deals, the exact metrics for marketing campaign effectiveness, and the precise contribution of point-of-sale discount programs to manufacturer solutions growth. Additionally, they deferred outlining strategic initiatives for 2026, stating that details would be shared in the next call.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Aid store
Amgen Repatha
DC
GoodRx brand
GoodRx name
Kroger pharmacy
Manufacturer Solutions
Novo Nordisk
TrumpRx
Wegovy
access GoodRx
access affordability
access saving
adoption
affordability access
affordability program
brand campaign
capability end
commerce experience
commitment
consumer access
convenience
counter solution
deal
evolution
hurdle
investment
loss
name prescription
nation
pharmacy access
pharmacy cost
saving patient
scale
strength
subscription offering
transparency consumer
treatment
value consumer
GDRX Transcript
GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call summary and Q&A indicate strong growth in Pharma Direct and condition-specific subscriptions, with optimistic guidance for 2026. Despite some uncertainties in partnerships and PTR revenue, the overall sentiment is positive due to expected revenue and EBITDA growth, as well as strong demand for GLP-1 therapies. The market cap suggests moderate stock price reaction, leading to a 'Positive' prediction (2% to 8%).
GoodRx Holdings, Inc. (GDRX) Q4 2025 Earnings Call Transcript
Positive2-26
The earnings call reveals strong growth prospects, including a 35% YoY increase in Manufacturer Solutions revenue and strategic investments in e-commerce and subscriptions, despite a slight revenue decline due to timing. Positive trends in Pharma Direct and increasing web traffic, alongside durable partnerships, indicate optimism. However, margin pressures and lower take rates are concerns, but the overall sentiment remains positive due to the company's strategic direction and market expansion efforts. The market cap suggests moderate stock volatility, aligning with a positive prediction.
GoodRx Holdings, Inc. (GDRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
GoodRx Holdings, Inc. (GDRX) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call summary and Q&A indicate strong growth prospects, particularly in manufacturer solutions and strategic initiatives, despite some headwinds like Rite Aid bankruptcy. The positive sentiment is reinforced by management's optimistic guidance and strategic focus on market expansion and partnerships. The market cap suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
GDRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
